Kyverna Therapeutics, Inc. Shareholders' Equity
Kyverna Therapeutics, Inc. (KYTX) had Shareholders' Equity of $165.55 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-11
- 2026-06-30: Stockholders' Equity Attributable to Parent $165.55M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $195.58M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $232.28M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $151.95M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $165.55M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $195.58M 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $232.28M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $151.95M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $184.38M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $224.01M 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $266.59M 10-Q · filed 2026-08-11 | |
| 2024-09-30 | $302.71M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $333.51M 10-Q · filed 2025-11-12 | |
| 2024-03-31 | $360.99M 10-Q · filed 2025-11-12 | |
| 2023-12-31 | -$13.14M 10-K · filed 2026-03-26 | -$131.40M 10-Q · filed 2024-05-14 |
| 2023-09-30 | -$111.81M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$97.19M 10-Q · filed 2024-11-13 | |
| 2023-03-31 | -$84.61M 10-Q · filed 2024-11-13 | |
| 2022-12-31 | -$74.00M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |